PFS
SNDX icon

Prospera Financial Services’s Syndax Pharmaceuticals SNDX Stock Holding History

Prospera Financial Services’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,781
Closed -$66K – 2468
2022
Q1 		$66K Buy
+3,781
New +$63.7K ﹤0.01% 1259
2020
Q4 		– Sell
-2,032
Closed -$30K – 1427
2020
Q3 		$30K Buy
+2,032
New +$31K 0.01% 777

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Prospera Financial Services's SNDX Position: Q2 2022 in Review

Prospera Financial Services sold out of Syndax Pharmaceuticals (SNDX) in Q2 2022, closing a stake of 3,781 shares — an estimated $66K sold.

Prospera Financial Services first reported a position in SNDX in Q3 2020 and held it in 2 quarters. The position peaked at $66K in Q1 2022. 121 funds tracked by Wall St. Rank hold SNDX as of Q2 2022.

  • Prospera Financial Services reported no remaining Syndax Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 3,781 Syndax Pharmaceuticals shares in Q2 2022, an estimated $66K.
  • Prospera Financial Services first reported a position in Syndax Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Prospera Financial Services's Syndax Pharmaceuticals position peaked at $66K in Q1 2022.
  • 121 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.